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ABSTRACT
Passive antibody therapy for cancer is an effective but costly treatment modality. Induction of
therapeutically potent anticancer antibodies by active vaccination is an attractive alternative but has
proven challenging in cancer due to tolerogenic pressure in patients. Here, we used the clinically relevant
cancer target Her2, known to be susceptible to targeting by antibody therapy, to demonstrate how potent
antibody can be induced by vaccination. A novel 44kD Her2 protein fragment was generated and found to
be highly effective at inducing anti-Her2 antibody including trastuzumab-like reactivities. In the tolerant
and spontaneous BALB-neuT mouse model of metastatic breast cancer this Her2-targeting vaccine was
only effective if the fragment was conjugated to a foreign immunogenic carrier; Fragment C of tetanus
toxin. Only the conjugate vaccine induced high affinity anti-Her2 antibody of multiple isotypes and
suppressed tumor development. The magnitude of CD4C T-cell help and breadth of cytokines secreted by
the CD4C T helper (Th) cells induced to the foreign antigen was critical. We used a highly efficient plant-
based bio-manufacturing process for protein antigens, magnICON, for vaccine expression, to underpin
feasibility of future clinical testing. Hence, our novel Her2-targeting conjugate vaccine combines
preclinical efficacy with clinical deliverability, thus setting the scene for therapeutic testing.
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Introduction
In the last two decades immunotherapy has evolved into a
breakthrough therapeutic modality for combating cancer.1 Pas-
sive monoclonal antibodies (Mabs) targeting antigens on can-
cer cells or stimulating antitumor immunity through the
release of blocking signals on T cells have shown significant
clinical benefits, extending survival of patients with primary
and metastatic cancers.2,3 Using vaccines to educate the
patient’s immune system to recognize tumor antigens is also
emerging as a clinically relevant concept. The first therapeutic
vaccine, Provenge4 was approved by the FDA in 2010 and sev-
eral cancer vaccines are in late stage clinical evaluation.5-9
Human epidermal growth factor receptor Her2, also known
as Neu, ErbB-2, or p185, has emerged as an important target
for cancer immunotherapy. Activation of Her2 through gene
amplification or mutations occurs in many solid tumors includ-
ing 20–30% of breast and ovarian cancers, and is linked to more
aggressive disease and poor prognosis.10-12 Like other members
of the epidermal growth factor receptor family, Her2 is a
receptor tyrosine kinase composed of an extracellular (EC)
domain, a transmembrane (TM) domain and an intracellular
(IC) domain which interacts with downstream signaling mole-
cules (Fig. 1A). Through homodimerisation, or heterodimerisa-
tion with other family members, Her2 can transduce
deregulated signals responsible for neoplastic behavior of
cells.13
A Mab targeting Her2, trastuzumab (Herceptin) alone or
linked with a cytotoxic drug DM1 (trastuzumab emtansine)
has had significant impact on survival rates from Her2 positive
metastatic breast cancer.14,15 More recently a second anti-Her2
Mab, pertuzumab, was approved in combination with Hercep-
tin and chemotherapy for untreated Her2/neu positive meta-
static breast cancer patients; the combination achieved
significant improvement in progression free and overall
survival.16
Clearly Her2 is an excellent target for antibody attack but
for passive Mab therapy a number of limitations arise, includ-
ing tumor recurrence within an year of treatment, reflecting
CONTACT Natalia Savelyeva N.Savelyeva@soton.ac.uk
Supplemental data for this article can be accessed on the publisher’s website.
*These authors contributed equally to this work.
#Joint senior authors.
Published with license by Taylor & Francis Group, LLC © Warayut Chotprakaikiat, Alex Allen, Duc Bui-Minh, Elena Harden, Jantipa Jobsri, Federica Cavallo, Yuri Gleba, Freda
K. Stevenson, Christian Ottensmeier, Victor Klimyuk, and Natalia Savelyeva.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/),
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the
named author(s) have been asserted.
ONCOIMMUNOLOGY
2016, VOL. 5, NO. 6, e1166323 (13 pages)
http://dx.doi.org/10.1080/2162402X.2016.1166323
development of antibody resistance.14 Additionally, the need
for repeated dosing to maintain protective antibody levels
imposes a significant burden on healthcare. Active immuniza-
tion, i.e. vaccination, can induce durable polyclonal antibody
responses, thus eliminating the need for multiple re-infusions
and reducing development of antibody resistance. Hence,
vaccination approaches for targeting Her2 (whole-cell vac-
cines, peptides, DNA encoding Her2 regions, viral vaccines
and Her2 protein fragments) have been developed and tested
in human clinical trials.17 In a recent phase I clinical trial, a
protein vaccine consisting of the Her2 EC domain and a por-
tion of the IC domain was given in combination with a
Figure 1. rED44Her2 and rED44Her2-FrC conjugate vaccines induce potent humoral immunity against rED44Her2 and native rHer2, and protect against challenge with
the TUBO mammary carcinoma. (A) Schematic representation of the Her2 molecule (highlighting the ED44Her2 fragment) and the ED44Her2-FrC conjugate vaccine
design. Diagram is representative of both the rat and human forms of Her2 and ED44Her2. (B) BALB/c wild type mice were primed and boosted 3 weeks later with
rED44Her2, rED44Her2-FrC or the plant expressed control vaccine, all in alum, or the EC-TM DNA vaccine (n D 5 per group). Antibody specific for the rED44Her2 fragment
was measured by ELISA. Serum was collected after priming, at week 3, and at week 5 which was 2 weeks after the boost. (C) Antibody able to bind native rHer2 expressed
on the surface of TUBO cells was measured by flow cytometry at week 5 and quantified using internal standards. (D) Correlation between the levels of anti-rED44Her2
antibody, as measured by ELISA, and anti-rHer2 antibody, as measured by binding to native rHer2 at the cell surface. Data from the rED44Her2 vaccine at week 5. r D the
Spearman’s rank correlation coefficient. (E) 6 weeks after the booster injection (week 9) mice were challenged with the transplantable TUBO mammary carcinoma, and
culled when tumors reached 15 mm diameter. In (B) and (C) each bar represents medians with individual mice displayed as dots. Mann–Whitney statistics are shown.
Log-rank (Mantel–Cox) test results shown in (E). ns D p > 0.05, p < 0.05, p < 0.01, p < 0.001. For (B) and (D) data from two experiments has been combined. For
(C) and (E) one representative experiment of three is shown.
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complex adjuvant that included TLR agonists. Anti-Her2 anti-
bodies were detectable, but showed limited anti-Her2 inhibi-
tory effects in vitro.18,19
A critical factor for induction of potent antibody responses
is the availability of cognate CD4C T-cell help, which drives B
cells through a germinal center reaction where selection based
on high affinity for antigen occurs, along with antibody iso-
type-switch.20 This ensures the subsequent antibody response
is of high quality, through improved antigen binding and
enhanced effector function via changing the antibody Fc por-
tion. Once the antibody response is induced, T-cell help
remains critical as high-affinity memory responses cannot be
maintained in its absence.21,22 In cancer, this T-cell help may
not be inducible by cancer antigens themselves as multiple
immune tolerogenic mechanisms exist to dampen induction of
CD4C Th cells to these self-proteins.23
To overcome tolerogenic mechanisms, we have developed
DNA vaccines incorporating the target antigen linked to a non-
toxic portion of Tetanus Toxin FrC24 or its subdomain Dom.25
This approach allowed the capture of CD4C T-cells from the
non-tolerized repertoire against foreign antigens, to enable
induction of immunity against cancer targets.25 These fusion
DNA vaccine designs have demonstrated induction of antibody
and CD8C T-cell responses in several phase I–II clinical trials
for both hematological26 and solid tumor targets27 with sugges-
tion of clinical benefit.62 DNA vaccines avoid the step of pro-
tein expression in vitro, and can induce high levels of cytotoxic
T cells,25,27,28 but the small amounts of protein produced in
vivo may not be ideal for activating B cells to produce optimal
levels of antibody.
We have now harnessed this principle of linked T-cell help
and exploited it for a protein vaccine to overcome tolerance to
Her2. We generated a novel 44kD protein fragment of the
Her2 EC domain (ED44Her2) to direct Her2 antibody specific-
ity and this was conjugated to FrC (ED44Her2-FrC). Both
vaccine subunits were expressed using plant-based bio-
manufacturing for proteins using magnICON methodology.29,30
This process has emerged in recent years as an efficient process
for achieving high levels of protein expression using plant viral
vectors to drive gene expression in non-transgenic plants.29,31
Since targeting Her2 with antibodies is therapeutically relevant,
for vaccine delivery we used formulation with alum which
aimed to focus the immune response on antibody induction
and is known not to induce functional CD8C cytotoxic T
cells.32,33 We demonstrate that this ED44Her2-FrC vaccine
design is able to induce potent antibody and overcome toler-
ance in a preclinical model of metastatic breast cancer. The
magnitude and breadth of cytokines produced by CD4C Th
cells engaged by conjugation to FrC resulted in generation of
high-affinity protective anti-Her2 antibody. Hence, the novel
vaccine has potential to become a plausible therapeutic option
for Her2 positive cancers.
Results
Her2 vaccine design and expression
To target Her2, we chose the 344 aa fragment that spans
domains III and IV of the Her2 EC domain, without
incorporation of the TM domain (Fig. 1A). This is the region
targeted previously by both trastuzumab34 and vaccination.35
We expressed this novel 44kD ED44Her2 protein in Nicoti-
ana benthamiana plants using the magnICON system.29 The
relatively high content of cysteine residues in the ED44Her2
fragment (29 cysteine residues or 8.5% of total amino acids)
caused a certain “stickiness” of the fragment, but this did not
have any significant impact on downstream processing. Both
the rat and human forms of ED44Her2 were generated. This
allowed testing in both the spontaneous breast cancer model
BALB-neuT that is driven by the activated rat Her2
transgene,36 or the transplantable D2F2/E2 mammary carci-
noma which is transfected with human Her2.37 Plant-
expressed FrC was also produced, and conjugated to either
rED44Her2 (rat) or hED44Her2 (human), in order to capture
non-tolerized CD4C Th cells to help B cells generate potent
antibody against Her2.
Vaccines containing the rED44Her2 fragment induce
antibody against native rHer2
To evaluate the ability of rED44Her2 and the rED44Her2-FrC
conjugate to induce antibody responses against native Her2, we
vaccinated BALB/c wild type (wt) mice with rED44Her2,
rED44Her2-FrC or a plant-expressed control vaccine, in com-
bination with the adjuvant alum. First, antibody specific for
rED44Her2 was measured by ELISA and Fig. 1B demonstrates
that similar levels of antibody were induced by both
rED44Her2 containing vaccines after both priming and booster
injections (measured at week 3 and week 5). The results were
compared to the “gold standard” vaccine for this model, a
DNA vaccine that encodes the entire Her2 EC plus TM
domains which has been shown to induce antibody against
rHer2.38 Here, we found the DNA vaccine induced low levels
of antibody to rED44Her2 in comparison with the protein vac-
cines containing rED44Her2 (Fig. 1B; p D 0.0007 for both vac-
cines at both time points).
Next, we determined antibody reactivity to native rHer2
expressed on the surface of mammary carcinoma TUBO cells
by flow cytometry. The antibody induced by both
rED44Her2 and the rED44Her2-FrC conjugate was able to
recognize native rHer2, and antibody levels between the two
vaccines were similar when compared after boosting at week
5 (Fig. 1C), paralleling the findings in ELISA. Both protein
vaccines induced over 5-fold higher anti-rHER2 antibody
than the rEC-TM DNA vaccine (Fig. 1C; p D 0.0159 for
rED44Her2 and p D 0.0079 for rED4Her2-FrC). Hence,
rED44Her2 and rED44Her2-FrC were able to induce high
levels of antibody against native surface expressed rHer2,
indicating that the rED44Her2 protein fragment used in
both vaccines folded well, mimicking the antigenic determi-
nant of native Her2. Conjugation to FrC did not appear to
affect the antigenic properties of rED44Her2.
Correlation between antibody levels measured by ELISA or
against native rHer2 further supported the preservation of criti-
cal antigenic properties in the rED44Her2 fragment, with simi-
lar correlations found with both unconjugated and conjugated
vaccines (Fig. 1D and Fig. S1). Furthermore, the data validated
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the usage of rED44Her2 for measuring responses against native
rHer2 by ELISA.
We next tested the ability of the rED44Her2-based vaccines
to protect against TUBO carcinoma challenge. Mice primed
then boosted at week 3 were challenged at week 9 and tumor
development followed. Both rED44Her2 containing vaccines
were able to protect 100% of mice, as was the rEC-TM DNA
vaccine, until the experiment was terminated at day 80. The
control vaccine group and the naive control group developed
terminal tumors between day 28 and day 38 (Fig. 1E).
The rED44Her2-FrC conjugate vaccine overcomes
tolerance and rapidly induces high levels of antibody in
BALB-neuT tolerant mice
By the age of 10 weeks, BALB-neuT female mice spontaneously
develop lesions in the mammary glands that give rise to metasta-
ses in the lung and bone marrow.39 Multiple tolerogenic mecha-
nisms have previously been found to dampen humoral and
cellular immunity to Her2 induced by the rEC-TM DNA vac-
cine.40 T regulatory cells were involved and found to increase in
number with tumor progression.40 We used this stringent
BALB-neuT model, in which both tolerance to Her2 and sponta-
neous cancer development challenge the immune response, to
test our rED44Her2-containing vaccines. BALB-neuT mice were
vaccinated once every 3 weeks, starting at 10 weeks of age, and
their survival followed. Both the rED44Her2 and rEC-TM DNA
vaccine extended survival by 3 weeks only compared to the con-
trol vaccine. In contrast, the rED44Her2-FrC conjugate per-
formed significantly better than the other two vaccines
(p < 0.0001 vs. either rED44Her2 or the rEC-TM DNA vaccine,
Fig. 2A) with 50% of the mice surviving long term (until experi-
ments were terminated after 20 weeks).
Since our vaccination protocol was focused on antibody
induction antibody levels were then compared in detail. In con-
trast to the experiments in wild type (wt) mice where both
rED44Her2 vaccines induced similar levels of antibody
(Fig. 1B), in the tolerant model the rED44Her2-FrC conjugate
vaccine primed significantly higher levels of antibody than
rED44Her2 (Fig. 2B; pD 0.0152). The difference was more pro-
nounced after the first booster injection, with average antibody
levels in the rED44Her2-FrC group more than 3 times higher
than in the rED44Her2 group (Fig. 2B; p D 0.0087). Although
antibody levels equalized after the second boost the conjugate
vaccine clearly demonstrated faster kinetics. At time points
later than week 8 antibody levels could not be compared as
mice in all groups except the rED44Her2-FrC group had died.
The rEC-TM DNA vaccine induced significantly lower levels of
anti-rED44Her2 antibody then either of the rED44Her2 con-
taining vaccines at all three timepoints (Fig. 2B), similar to the
data in wt mice (Fig. 1B).
The rED44Her2-FrC conjugate vaccine induces CD4C T cell
help of a high magnitude and wide range, and hence
induces high-quality antibody immunity
We next probed the ability of the two rED44Her2 vaccines to
induce CD4C Th cells in BALB-neuTmice. Mice were vaccinated
with rED44Her2, rED44Her2-FrC or the control vaccine, all in
alum, and specific Th cells were enumerated after in vitro restim-
ulation with rED44Her2, FrC or a control protein. ELISPOT was
used to detect Th cells secreting cytokines IL-2, IL-4 or IFNg.
Figure 2. The rED44Her2-FrC conjugate vaccine affords superior protection against spontaneous mammary carcinoma in the BALB-neuT model, and induces high levels of
anti-rED44Her2 antibody. (A) BALB-neuT mice aged 10 weeks were vaccinated with rED44Her2, rED44Her2-FrC or the irrelevant control protein vaccine, in alum, or the EC-
TM DNA vaccine. They were then boosted every 3 weeks (see arrows on graph). Development of spontaneous tumors was observed and mice terminated when the sum
total mean diameter of tumors exceeded 15 mm. (B) Serum samples from mice in (A) were tested for rED44Her2-specific antibody at the indicated time points by ELISA.
In (A) log-rank (Mantel–Cox) test results are shown, and in (B) median values are plotted as bars, with Mann–Whitney statistics. Ns D p > 0.05, p < 0.05, p < 0.01,
p < 0.0001. Data combined from two experiments.
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The rED44Her2 vaccine induced low numbers of IL-2 and
IL-4 secreting Th cells, and the number of IFNg secreting cells
only just reached the threshold (Fig. 3A). These Th cells were
rED44Her2-specific and not FrC-specific, as expected. Conju-
gation to FrC did not improve the magnitude or range of
rED44Her2-specific Th cells (p > 0.05), but did induce large
numbers of FrC-specific Th cells secreting the three cytokines.
This implies the increase in antibody levels seen with the conju-
gate vaccine (Fig. 2B) was due to the improved Th response
induced by the rED44Her2-FrC vaccine. Of note, in wt BALB/c
mice the rED44Her2 vaccine was able to induce high numbers
of rED44Her2-specific Th cells secreting the three cytokines
(Fig. S2A)which suggests the failure in BALB-neuT mice was
due to Her2 tolerance.
T-cell help guides antibody isotype switch, with a clear link
between Th-derived IFNg and IgG2a, and between IL-4 and
IgG1.41 We found the poor ability of the rED44Her2 vaccine to
induce IFNg in tolerant mice resulted in the almost complete
lack of vaccine-specific IgG2a induced (1/6 mice positive,
Fig. 3B). The rED44Her2-FrC conjugate vaccine did induce
IgG2a, in keeping with Th IFNg induction. Concurrent with
the reduced number of IL-4 secreting Th cells, less IgG1 was
found with the rED44Her2 vaccine in comparison with the
rED44Her2-FrC vaccine (Fig. 3B; p D 0.0087). With the Th-
dependent isotype IgG2b, higher levels were again induced by
the rED44Her2-FrC vaccine. As before, in the wt BALB/c mice
the rED44Her2 vaccine could induce all three Th-dependent
antibody isotypes, similarly to the conjugate vaccine (Fig. S2B).
Given the pivotal role of T-cell help in antibody affinity
maturation, we next compared the affinity of the induced
antibody using a chaotropic ELISA.42 Higher affinity anti-
body is less affected by the chaotropic agent, therefore,
more remains bound to the plate. We found the conju-
gated rED44Her2-FrC vaccine induced significantly higher
affinity antibody than the unconjugated vaccine (Fig. 3C;
p D 0.0173).
Figure 3. The rED44Her2-FrC conjugate vaccine induced potent CD4C Th cell responses in BALB-neuT tolerant mice, which correlated with induction of a broad range of
IgG antibody isotypes, and antibody of high affinity. (A) Tolerant BALB-neuT mice were vaccinated with either the rED44Her2-FrC conjugate vaccine, the rED44Her2 vac-
cine or a control vaccine (3–5 mice per group from three independent experiments). Spleens were taken at day 14 and the number of CD4C Th cells secreting cytokines
IL-2, IL-4 or IFNg were measured by ELISpot after restimulation with rED44Her2 protein, FrC protein or an irrelevant control protein (Ovalbumin). The mean spot forming
units (SFU) per 106 lymphocytes (with SEM) from each group of mice is plotted, with non-specific background values (restimulation with media alone) subtracted. The
cut-off line represents 2 times responses from mice vaccinated with the control vaccine, or responses to the control protein, whichever was highest. Mann–Whitney statis-
tics are shown, between rED44Her2 stimulated groups. NsD p> 0.05. (B) Antibody isotypes (IgG1, IgG2a and IgG2b) were measured by ELISA in BALB-neuT tolerant mice
at week 5, following both priming and boosting with the rED44Her2-FrC or rED44Her2 vaccines, in alum. (C) Antibody affinity was measured using a chaotropic ELISA.
Affinity index indicates the concentration of chaotropic agent required to reduce antibody binding by 50%, with higher affinity antibody requiring a higher concentration
to disrupt binding. Serum was taken at week 5, as in (B). In (B) and (C) medians are plotted with data pooled from three independent experiments with similar results.
Mann–Whitney statistics are shown, with p < 0.05, p < 0.01.
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Hence through the FrC portion, the rED44Her2-FrC conju-
gate vaccine was able to induce high levels of Th cells which
secreted a wider range of cytokines than the unconjugated
rED44Her2 vaccine. This resulted in not only higher levels of
antibody (Fig. 2B) but in also in higher antibody affinity and
multiple IgG isotypes.
Foreign T-cell help is a critical component to overcome
tolerance and induce potent antibody
We next investigated whether T-cell help could be substi-
tuted by other stimuli such as adjuvants which can activate
B cells directly. Monophosphoryl lipid A (MPL) is a known
LPS-derived ligand for toll-like receptor 4 (TLR4), clinically
approved for use in combination with alum in the
prophylactic vaccine against human papilloma virus (HPV)
(Cervarix).43 MPL was also included in the clinical trial
using a Her2 protein vaccine consisting of the EC domain
plus a portion of the IC domain.18 We evaluated the
rED44Her2 vaccine in combination with MPL plus alum
and compared responses to the unconjugated or conjugated
vaccine with alum alone, to see whether adding the MPL
adjuvant could compensate for the lack of T-cell help. In a
separate group MPL was added to the rED44Her2-FrC vac-
cine in alum, to test whether further improvement of this
vaccine could be achieved.
Fig. 4A shows that after priming (at week 3) inclusion of
MPL did enhance antibody levels above that induced with
rED44Her2 in alum alone (pD 0.028). The difference was even
more apparent at week 5 (after boosting, pD 0.0048). Antibody
Figure 4. TLR4 agonist MPL cannot compensate for lack of T-cell help in terms of antibody affinity, IgG isotype induction or protection from spontaneous tumor develop-
ment. BALB-neuT mice (n D 3–5 per group) were vaccinated with either rED44Her2 or rED44Her2-FrC, in alum or in combination with alum plus MPL. Serum was taken
after priming, at week 3, or after boosting, at week 5. (A) Anti-rED44Her2 antibody levels measured by ELISA. (B) IgG antibody affinity from week 3 samples was measured
by a chaotropic ELISA, and the affinity index calculated. (C) Levels of IgG isotypes were measured from serum samples taken at week 5. Medians are plotted, with Mann–
Whitney statistics shown. Ns D p > 0.05, p < 0.05, p < 0.01, p < 0.001. (D) Survival of BALB-neuT mice from the spontaneous development of mammary tumors
was followed after the above vaccination protocol. Mice were culled when total mean diameter of the tumors reached 15 mm. Log-rank (Mantel–Cox) statistics shown.
Ns D p > 0.05, p < 0.05. Due to the limited number of BALB-neuT mice available, results from two experiments showing the same trends have been combined in (A),
(B), (C) and (D).
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levels induced by rED44Her2 in alum plus MPL were compa-
rable to those in the rED44Her2-FrC group (p> 0.05), indicat-
ing that in terms of antibody levels MPL could replace T cell
help. However, when we measured antibody affinity it became
clear that addition of MPL did not yield any improvement in
affinity above that in the rED44Her2 plus alum group (p >
0.05, Fig. 4B), and the affinity was significantly lower than in
the rED44Her2-FrC conjugate vaccine group (p D 0.0002).
Hence the enhancement of antibody levels in rED44Her2 plus
MPL group was because of an increase in low-affinity antibody.
MPL also failed to enhance the levels of IgG1 or IgG2a when
added to the rED44Her2 vaccine (Fig. 4C), but did increase
IgG2b levels (p D 0.048). In terms of impact on protection,
MPL provided modest improvement of survival over that by
the rED44Her2 vaccine in alum alone (Fig. 4D; p D 0.0413),
but was less effective than the conjugate vaccine in alum alone
(pD 0.0358). Finally addition of MPL failed to make any differ-
ence to the overall performance of rED44Her2-FrC vaccine
(Figs. 4A–D).
Performance of an ED44Her2-FrC clinical candidate
vaccine
The next step was to identify a candidate vaccine for clinical
testing. Results generated in the BALB-neuT model suggest the
rED44Her2-FrC conjugate is clearly more potent at protecting
against cancer than the unconjugated rED44Her2 vaccine
(Fig. 2A). Vaccines containing rat Her2 fragments have been
proposed as xenogeneic vaccine candidates for human use.44
Therefore, we tested the rat ED44Her2-FrC in the transplant-
able D2F2/E2 model of breast cancer, which expresses human
Her2 (hHer2). Wt BALB/c mice were vaccinated with
rED44Her2-FrC using the same protocol as for the TUBO
model (at week 0 and week 3) and then at week 8 they were
challenged with the D2F2/E2 tumor. No protection was induced
by the rat version of the vaccine in comparison with the group
which received the control vaccine (p > 0.05, Fig. 5A). This was
in keeping with low levels of antibody able to bind native hHer2
on the surface of D2F2/E2 cells, as measured by FACS (Fig. 5B).
We then used the human version of the ED44Her2-FrC
Figure 5. Evaluation of the rat and human ED44Her2-FrC conjugate vaccines in the D2F2/E2 model which expresses hHer2. (A) Wild type BALB/c mice (n D 4–6 per group)
were vaccinated twice with the vaccines indicated (at week 0 and week 3) and at week 8 were challenged with 5 £ 105 D2F2/E2 mammary carcinoma cells. Survival was fol-
lowed from the day of tumor challenge, with mice culled when total tumor diameter reached 15 mm. Log-rank (Mantel–Cox) statistics are shown, ns D p > 0.05, p < 0.01.
(B) Levels of anti-hHer2 antibody were quantified by analysis of binding to native hHer2 expressed on the surface of D2F2/E2 cells by FACS. Quantification was relative to inter-
nal standards. Bars are median values, with Mann–Whitney statistics shown, p < 0.05, p < 0.01. C. Competition assay in which binding of sera from hED44Her2-FrC-vacci-
nated mice to hHer2 on D2F2/E2 cells was detected by FACS in the presence of varying concentrations of trastuzumab or control Mab (rituximab). Mean values with standard
deviations from groups of four individual mice are shown. Data are representative of three (A) and (B) or two (C) independent experiments.
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conjugate vaccine in the D2F2/E2 model and this induced sig-
nificant protection, with approximately 80% of mice remaining
tumor free until the experiment was terminated 70 d after
tumor challenge (Fig. 5A; p D 0.0018). Protection was in keep-
ing with higher levels of anti-hHer2 antibody, measured by
FACS using D2F2/E2 cells (Fig. 5B; pD 0.0043).
Since the hED44 contained the region of Her2 that is recog-
nized by trastuzumab, we were curious whether our vaccine
induced reactivities similar to trastuzumab. We conducted a
Her2 binding assay in the presence of trastuzumab, pertuzu-
mab or control Mab. Trastuzumab-like reactivity was induced
by the hED44Her2-FrC vaccine because trastuzumab but not
the control Mab was able to block hHer2 binding of the
immune sera (Fig. 5C). Since the immune sera still retained
binding to Her2 even at saturating concentrations of trastuzu-
mab (1 mg/mL), reactivities directed to other epitopes were
clearly present. Pertuzumab which binds to Her2 outside of the
hED44 region45 did not prevent binding of the immune sera as
expected (Fig. S3). The combination of the two Mabs showed
similar effects to trastuzumab alone (Fig. S3).
Discussion
Here we propose a clinically relevant strategy for inducing pro-
tective antibody against Her2, using a conjugate protein vaccine
in which a novel Her2 fragment is conjugated to the FrC car-
rier. To facilitate transition into the clinic, we used the magnI-
CON system for vaccine expression and preparation.30 This
innovative approach assures fast and cost-effective antigen pro-
duction46 which was made possible via the use of plant-viral
vectors to drive gene expression in non-transgenic plants.30 A
plant-based approach has recently been used for production of
the rat Her2 EC domain and, in a preliminary study, was shown
to be, effective at inducing protective antibody in wt mice.47 In
our study, we reduced the size of the EC domain to a smaller
fragment (ED44), a strategy that often leads to higher levels of
expression.
The magnICON approach has been validated for delivery of
clinical grade cancer vaccines and antibodies. In the Phase I,
clinical trial for non-Hodgkins lymphoma magnICON
manufacturing produced patient specific vaccines targeting
idiotypic antigen.48 In addition, during the 2014 West African
Ebola outbreak, three humanised Mabs against the Ebola virus
(ZMapp) were manufactured using magnICON and have been
successfully used to treat infected patients.49 Although no toxic-
ity has been demonstrated with these plant-expressed biologics
per se the ability to raise a strong polyclonal antibody response
against Her2 raises the question of potential cardiotoxicity
which has been documented with trastuzumab treatment in
patients with Her2 positive breast cancer.50 This may be linked
to transient Her2 expression upon combination with anthracy-
cline therapy.51 Interestingly no increase of cardiac adverse
events was observed in patients when two Mabs pertuzumab
and trastuzumab were combined,52 indicating that targeting
more than one epitope may in fact be advantageous. However,
since vaccine-induced antibody is more difficult to withdraw,
this aspect will need cautious assessment.
Multiple layers of tolerance to Her2 exist in patients, which
vaccination will need to overcome to induce protective
immunity through antibody. In the BALB-neuT model, toler-
ance similarly affects the CD4C T-cell and B-cell compart-
ments. Central tolerance of CD4C T-cells is incomplete and
peripheral tolerance deepens as the tumor grows and the fre-
quency of regulatory T-cells increases,40 conceptually repro-
ducing events that govern failure of immune control in
patients. In the Balb-NeuT model, the major protective mecha-
nism is antibody as a number of vaccines including the “gold
standard” DNA vaccine failed to protect in antibody deficient
mice (Balb-NeuTmKO).38,53,54 Hence, the function of tumor-
antigen-specific B cells is a critical factor for anti-Her2 vacci-
nation. In the BALB-neuT model, the B-cell compartment will
be subjected to tolerogenic mechanisms which operate to
silence self-reactive B cells.55 These include deletion or func-
tional silencing (anergy), which depends on whether antigen is
cell-surface bound or present in a soluble form, respectively.55
Since in the BALB-neuT model Her2 is cell-surface expressed
but also present in a soluble form, involvement of both dele-
tion and anergy is expected.
It is therefore remarkable that despite these tolerogenic
mechanisms unconjugated vaccines were still able to induce
antibody; however, the induced antibody was suboptimal and
provided poor protection. We demonstrate that provision of
sufficient T-cell help through conjugation to FrC was able to
overcome tolerance and induce better quality antibody than the
unconjugated vaccine: antibody of higher affinity and multiple
IgG isotypes was induced (Fig. 6). The unconjugated vaccine
induced low levels of Th cells which secreted IL-2 and IL-4,
while cells that secreted IFNg were almost undetectable. Conju-
gation to FrC was able to improve Th induction by engaging
FrC-specific subsets able to secrete the three cytokines.
Our data suggest that the presence of FrC in the conjugate
vaccine supports class switching to IgG2a. IgG2a antibody, or its
human analog IgG1, is crucial for cytolysis of cancer cells due to
superior binding of Fc receptors on innate immune cells which
facilitate phagocytosis and antibody-dependent cell-mediated
cytotoxicity. IgG isotypes are unlikely to be relevant for anti-
body-mediated direct inhibition of tumor cell growth (for exam-
ple by down-modulation of Her2 signaling) but antibody affinity
is expected to be critical. We found a significant increase in anti-
body affinity with the rED44Her2-FrC vaccine compared to the
unconjugated vaccine. Our data suggest that the combination of
both more desirable antibody isotype and higher affinity delivers
the best outcome, with increased survival benefit found in the
case of the conjugate vaccine.
Addition of adjuvant MPL to the unconjugated rED44Her2
vaccine contributed to an overall increase of anti-Her2 anti-
body, but was not linked to increased antibody affinity. This
indicates that if insufficient T-cell help is available the extrafol-
licular pathway for antibody generation56 prevails over the ger-
minal center pathway, and the quantitative increase in
antibody following MPL addition was accounted for by low-
affinity antibody. A clinical study using a dHer2 (EC plus IC
portion) protein vaccine not conjugated to a carrier but com-
bined with a complex adjuvant that included MPL, found that
induced antibody was not able to sufficiently inhibit Her2 in
vitro.19 Although affinity results were not reported, our data
suggest this outcome could have resulted from induction of
low-affinity anti-Her2 antibody.
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It appears that inclusion of large protein carriers is superior
to individual helper epitopes. For example, inclusion of the p30
universal helper epitope from FrC into a Her2-EC protein vac-
cine did not result in significant protection in the FVB/Nneu
spontaneous breast cancer model.57 This is most likely because
a large protein can engage a wider CD4C T cell repertoire and
so deliver larger quantities of T-cell help. The quantitative ele-
ment of T-cell help is important and a known limiting factor
for generating high-affinity antibody.20 In the clinic a single
helper epitope, even if promiscuous for multiple MHC II
alleles, is unlikely to be effective in an unselected patient popu-
lation. For maximal antibody induction, we selected the full-
length FrC sequence which we have shown to be effective with
a range of antigens.25 The sequence consisting of a single-
domain Dom of FrC was designed for vaccines aimed to induce
CD8C T-cell responses against attached peptide sequences58
and was not used here. Rat Her2 has more than 80% homology
to the human molecule,59 and both rat and chimeric versions
of the EC-TM DNA vaccine have been used to generate immu-
nity against human Her2 positive tumors.44 Therefore, the rat
version of the conjugate vaccine (rED44Her2-FrC) was tested
for the ability to protect against the hHer2C D2F2/E2 breast
carcinoma. rED44Her2-FrC was not able to protect mice from
D2F2/E2 tumor challenge, hence a human version of the
ED44Her2-FrC vaccine was developed. This version was excel-
lent at inducing hHer2-specific antibody and protected 80% of
mice in the prophylactic model. Remarkably hED44Her2-FrC
was able to induce trastuzumab-like reactivities but also tar-
geted unknown epitopes of hHer2. As immune effectors, anti-
bodies have proven powerful at achieving remarkable
antitumor efficacy and appear less affected by tolerogenic
mechanisms operating in the tumor microenvironment, partic-
ularly in solid tumors.2 This reassures that optimally-induced
humoral immunity could be a very powerful antitumor ther-
apy. The formulation of alum and MPL was previously demon-
strated to induce functional CTLs.32 However, in our study no
additional protection was observed when MPL, was added to
the vaccine formulation, arguing that antibody is the necessary
and sufficient for protection. Although co-induction of cyto-
toxic T cells is desirable, the ability of this arm of the immune
response to control the tumor appears to encounter difficulties
linked to the immunosuppressive microenvironment in the
tumor itself.
Induction of powerful polyclonal antibody without the cyto-
toxic T-cell arm of the immune response could be sufficient for
clinical success of the ED44Her2-FrC conjugate vaccine. How-
ever one can assume that multiple immune effectors will work
synergistically and benefit the patient, although whether this is
the case remains to be seen.
Materials and methods
Production of plant-derived vaccines
The rat ED44Her2 (rED44Her2) sequence (GenBank accession
no. NP_058699, residues 314–657) was generated from rat
cDNA by PCR and the human ED44Her2 (hED44Her2)
sequence (GenBank accession number AAA75493, amino acid
residues 310–653) was generated using gene synthesis with the
codon usage of Nicotiana tabacum. The FrC sequence encoding
the non-toxic C-terminal portion of Tetanus toxin, (Swiss-Prot
accession no. P04958, amino acid residues 865–1315) was gen-
erated by gene synthesis.
rED44Her2, hED44Her2 and FrC protein was produced
using magnICON methodology.30 For further details see sup-
plementary material. Briefly, the DNA sequences were cloned
Figure 6. Proposed mechanism of action for the ED44Her2-FrC conjugate vaccine versus the unconjugated vaccine.
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into Tobacco mosaic virus (TMV) based viral expression vec-
tors, then Agrobacterium containing the vectors were prepared
as described31 and used to infiltrate Nicotiana benthamiana
plants. 7–12 d later plant leaves were harvested, and the pro-
teins purified by affinity chromatography. rED44Her2 and
hED44Her2 were conjugated to FrC using glutaraldehyde, see
supplementary material.
Mice and vaccination protocols
BALB/c and BALB-neuT female mice, aged 10 weeks at the
beginning of procedures, were kept in accordance with the UK
Home Office Guidelines. BALB-neuT mice express the rHer2
oncogene under the mouse mammary tumor virus promoter
on a BALB/c background,36 and spontaneously develop mam-
mary tumors palpable by 12 weeks of age.
Mice were injected with 50 mg of rat or human ED44Her2,
or the ED44Her2-FrC conjugates containing an equivalent
amount of ED44Her2. At both priming and boosting the vac-
cines were combined with an equal volume of alum adjuvant
(Sigma) and injected subcutaneously into two sites in the flank.
In some experiments 10 mg per mouse of monophosphoryl
lipid A (MPL, Invivogen) was added to alum as an additional
adjuvant. An equivalent amount of plant-expressed irrelevant
protein (idiotypic Ig from the 5T33 mouse myeloma fused to
FrC,21 made by Icon Genetics) was used as a control vaccine.
50 mg of a DNA vaccine encoding the EC and TM portions of
Her2 (Her2-EC-TM DNA vaccine38) was injected intramuscu-
larly into both quadriceps. BALB/c mice were boosted 3 weeks
after priming with the same amount of protein or DNA as at
priming. BALB-neuT mice were vaccinated 6 times with a 3-
week interval between vaccinations. The same amount of pro-
tein used at priming was used for the first boost, then half the
amount was used for subsequent boosts.
Mouse mammary carcinoma cell lines
TUBO cells were cloned from a lobular mammary carcinoma
which developed in a BALB-neuT mouse, and therefore express
rHer2.60 They were cultured in complete DMEM with high glu-
cose (PAA Laboratories, with added 20% fetal calf serum (FCS),
50 U/mL penicillin and 50 mg/mL streptomycin).
The mammary tumor line D2F2/E2, which were derived
from a BALB/c mouse and stably transfected with the human
Her2 gene,37 were cultured in complete DMEM with high glu-
cose, supplemented with 800 mg/mL of selective antibiotic
G418 (Gibco). Single-cell suspensions were prepared by passing
the cells through a syringe after trypsinisation. Both the TUBO
and D2F2/E2 cell lines were a kind gift from Professor Lollini,
University of Bologna, Italy.
Measurement of Her2ED44-specific total IgG antibody, IgG
isotypes and antibody affinity by ELISA
Nunc Maxisorp ELISA plates were coated overnight with 3 mg/
mL rED44Her2 or hED44Her2. Following blocking with 1%
bovine serum albumin (BSA) in phosphate buffered saline
(PBS), serial dilutions of serum were incubated on the plate for
1.5 h at 37C. Horseradish peroxidase (HRP) labeled anti-
mouse IgG (The Binding Site), anti-IgG1 (Oxford Biotechnolo-
gies), anti-IgG2a (Serotec) or anti-IgG2b (Harlan Sera-Lab
Ltd.) were added for a further 1.5 h at 37C, followed by incu-
bation with o-phenylenediamine dihydrochloride substrate
(Sigma). Internal standards were generated as previously
described24 and a standard curve used to calculate serum anti-
body levels.
Chaotropic ELISAs to measure antibody affinity followed
the above protocol, with addition of chaotropic agent ammo-
nium thiocyanate (serially diluted from 6M) following serum
incubation.42 Binding of higher affinity antibodies to the coat-
ing antigen is less disrupted by the chaotropic agent, therefore
more remain bound to the plate and are detected by the sec-
ondary antibody. The affinity index was calculated as the con-
centration of ammonium thiocyanate required to achieve a
50% reduction in bound antibody, compared to wells with no
ammonium thiocyanate (100%).
Antibody binding to native Her2
A FACS assay to measure the extent induced antibodies could
bind to native Her2 expressed on the cell surface was modified
from Rovero et al.60 Briefly, 2 £ 105 TUBO cells expressing
rHer2, or D2F2/E2 cells expressing hHer2, were blocked with
non-specific mouse serum then incubated with serial dilutions
of serum from vaccinated mice. Binding of vaccine-induced
antibody to native Her2 was detected using eFluor660-labeled
polyclonal anti-mouse IgG (eBioscience). A standard curve was
generated using pooled serum samples, and the relative binding
of induced serum antibodies was estimated from this. An unla-
beled monoclonal anti-Her2 antibody (Ab-4 for rHer2, Ab-5
for hHer2, both Calbiochem) was used as a positive control.
Detection of trastuzumab-like reactivities in the immune
sera
D2F2/E2 cells treated as for antibody binding were pre-incu-
bated with trastuzumab, pertuzumab or negative control rituxi-
mab (all from Roche) Mabs at a range of increasing
concentrations (0.001–10 mg/mL to reach saturating concentra-
tion) for 30 min on ice before individual or pooled sera from
mice vaccinated with hED44-FrC was added and incubated for
a further 30 mins. The mouse serum samples were obtained at
week 7 from Balb/c mice vaccinated twice with hED44Her2-
FrC as described above. Binding of the immune serum was
detected using PE-labeled anti-mouse IgG Fc-specific antibody
(Jackson ImmunoResearch, PA, USA) using FACSCalibur with
Cell Quest Pro (BD Biosciences) and FlowJo (Tree Star Inc.,
Oregon, USA) software.
Tumor protection experiments
In BALB/c mice protection experiments were performed using
the TUBO (rHer2) or the D2F2/E2 (hHer2) cell lines. After two
doses of vaccine (at week 0 and week 3) mice were challenged
subcutaneously with 1 £ 105 tumor cells. The challenge was 4–
6 weeks after the last vaccination. Once the tumors reached
15 mm mean diameter the mice were culled. In BALB-neuT
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protection experiments, culling took place when the sum total
of tumor diameter reached 15 mm.
ELISpot detection of vaccine induced Th cell responses
The ELISpot protocol for detecting Th responses after a protein
vaccination was developed previously.61 Briefly, plates were
coated overnight with anti-IFNg, anti-IL-2 or anti-IL-4 anti-
body (BD Bioscience). 14 days after vaccination with
rED44Her2, rED44Her2-FrC or the irrelevant control vaccine
(plant expressed 5T33 Ig, not fused to FrC) spleens were proc-
essed. Following lymphoprep density centrifugation lympho-
cytes were plated at 2.5 £ 105 per well in RPMI 1640 media
supplemented with 10% FCS, 1 mM sodium pyruvate, 2 mM
glutamine, 1% non-essential amino acids, 50 U/mL penicillin,
50 mg/mL streptomycin and 50 mM b-mercaptoethanol. The
cells were restimulated in vitro with media alone, 10 mg/mL
rED44Her2, 10 mg/mL FrC or 10 mg/mL control protein
(EndoGrade Ovalbumin, Hyglos GmbH). Following 40 h of
restimulation, cytokine secretion was detected using cytokine-
specific biotinylated antibodies, and then streptavidin-ALP
(MAbtech AB). Spots were revealed using BCIP/NBT substrate
(Invitrogen) and enumerated using an ELISpot microplate
reader (AID GmbH). The non-specific media alone back-
ground was subtracted, and the response considered positive if
the number of spots was more than twice that of the control
mice or to the control protein, whichever was highest.
Statistical analysis
Non-parametric Mann–Whitney statistics were used for com-
parison between groups, with p < 0.05 taken as significant. The
Spearman’s rank correlation coefficient, calculated using
GraphPad Prism, was used to assess correlation between ELISA
and FACS data. For curve comparison in survival experiments
the Log-rank (Mantel–Cox) test was performed.
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